Loading clinical trials...

Coronavirus Disease (COvid-)19 REgistry on THROMBOSIS Complications | Clinical Trials | Clareo Health

COMPLETED

Coronavirus Disease (COvid-)19 REgistry on THROMBOSIS Complications

COvid-19 REgistry on THROMBOSIS Complications Associated With Hospitalization

NCT04780295•Johannes Gutenberg University Mainz

Summary

This online-based, observational retrospective registry aims to (i) study the rate of cardiovascular events, encompassing venous thromboembolic and arterial events, in consecutive hospitalized patients with coronavirus (Covid19), (ii) investigate the prevalent use of thromboprophylaxis, (iii) describe the use of imaging tests for the detection of cardiovascular events in patients with Covid19. This will also facilitate and constitute the basis for the conduction of interventional thromboprophylaxis studies in patients with Covid19.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Hospitalized patients aged ≥ 18 years with a positive test for severe acute respiratory syndrome corona virus 2 (SARS-CoV2)

Exclusion Criteria

•None

Locations (30)

Unicamp (Universidade Estadual de Campinas; University of Campinas)

Campinas, Brazil

Hospital Sírio-Libanês

São Paulo, Brazil

Hospital de Campanha Anhembi

São Paulo, Brazil

Amager and Hvidovre Hospital

Hvidovre, Denmark

Universitätsklinikum Koeln

Cologne, Germany

Augusta-Krankenhaus Duesseldorf

Düsseldorf, Germany

Universitäts-Herzzentrum Freiburg

Freiburg im Breisgau, Germany

Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes

Homburg, Germany

DRK Kliniken Berlin Köpenick

Köpenick, Germany

Universitätsmedizin Mainz

Mainz, Germany

Key Dates

Start Date

April 15, 2020

Primary Completion Date

May 18, 2021

Completion Date

May 18, 2021

Last Updated

January 25, 2023

Enrollment

2,708

ACTUAL participants

Conditions

Covid19

The Effect of the Covid-19 Pandemic Among Operated Patients

NCT04525716

Covid19Surgery

View study

RECRUITINGPHASE3

The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients

NCT03188796

Critical IllnessVitamin D Deficiency+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 25, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Coronavirus Disease (COvid-)19 REgistry on THROMBOSIS Complications

Inclusion Criteria

Exclusion Criteria

The Effect of the Covid-19 Pandemic Among Operated Patients

The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients

Covid-19 and Influenza Oral Vaccine Study

Conversations You Want About Corona Virus Disease (COVID-19)

Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19

COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy